455 related articles for article (PubMed ID: 26786929)
1. Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma.
Happold C; Gorlia T; Chinot O; Gilbert MR; Nabors LB; Wick W; Pugh SL; Hegi M; Cloughesy T; Roth P; Reardon DA; Perry JR; Mehta MP; Stupp R; Weller M
J Clin Oncol; 2016 Mar; 34(7):731-9. PubMed ID: 26786929
[TBL] [Abstract][Full Text] [Related]
2. Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme.
Kerkhof M; Dielemans JC; van Breemen MS; Zwinkels H; Walchenbach R; Taphoorn MJ; Vecht CJ
Neuro Oncol; 2013 Jul; 15(7):961-7. PubMed ID: 23680820
[TBL] [Abstract][Full Text] [Related]
3. Survival benefit of levetiracetam in patients treated with concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide for glioblastoma multiforme.
Kim YH; Kim T; Joo JD; Han JH; Kim YJ; Kim IA; Yun CH; Kim CY
Cancer; 2015 Sep; 121(17):2926-32. PubMed ID: 25975354
[TBL] [Abstract][Full Text] [Related]
4. Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide.
Redjal N; Reinshagen C; Le A; Walcott BP; McDonnell E; Dietrich J; Nahed BV
J Neurooncol; 2016 May; 127(3):505-14. PubMed ID: 26830093
[TBL] [Abstract][Full Text] [Related]
5. A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.
Krauze AV; Myrehaug SD; Chang MG; Holdford DJ; Smith S; Shih J; Tofilon PJ; Fine HA; Camphausen K
Int J Radiat Oncol Biol Phys; 2015 Aug; 92(5):986-992. PubMed ID: 26194676
[TBL] [Abstract][Full Text] [Related]
6. Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma.
Weller M; Gorlia T; Cairncross JG; van den Bent MJ; Mason W; Belanger K; Brandes AA; Bogdahn U; Macdonald DR; Forsyth P; Rossetti AO; Lacombe D; Mirimanoff RO; Vecht CJ; Stupp R
Neurology; 2011 Sep; 77(12):1156-64. PubMed ID: 21880994
[TBL] [Abstract][Full Text] [Related]
7. Valproic acid use during radiation therapy for glioblastoma associated with improved survival.
Barker CA; Bishop AJ; Chang M; Beal K; Chan TA
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):504-9. PubMed ID: 23523186
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of levetiracetam, valproate and carbamazepine among elderly patients with newly diagnosed epilepsy: subgroup analysis of the randomized, unblinded KOMET study.
Pohlmann-Eden B; Marson AG; Noack-Rink M; Ramirez F; Tofighy A; Werhahn KJ; Wild I; Trinka E
BMC Neurol; 2016 Aug; 16(1):149. PubMed ID: 27552848
[TBL] [Abstract][Full Text] [Related]
9. Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade glioma.
Watanabe S; Kuwabara Y; Suehiro S; Yamashita D; Tanaka M; Tanaka A; Ohue S; Araki H
Eur J Clin Pharmacol; 2017 Mar; 73(3):357-363. PubMed ID: 27889835
[TBL] [Abstract][Full Text] [Related]
10. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
[TBL] [Abstract][Full Text] [Related]
11. Use of metformin and outcome of patients with newly diagnosed glioblastoma: Pooled analysis.
Seliger C; Genbrugge E; Gorlia T; Chinot O; Stupp R; Nabors B; Weller M; Hau P;
Int J Cancer; 2020 Feb; 146(3):803-809. PubMed ID: 30980539
[TBL] [Abstract][Full Text] [Related]
12. Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.
Sandmann T; Bourgon R; Garcia J; Li C; Cloughesy T; Chinot OL; Wick W; Nishikawa R; Mason W; Henriksson R; Saran F; Lai A; Moore N; Kharbanda S; Peale F; Hegde P; Abrey LE; Phillips HS; Bais C
J Clin Oncol; 2015 Sep; 33(25):2735-44. PubMed ID: 26124478
[TBL] [Abstract][Full Text] [Related]
13. KOMET: an unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy.
Trinka E; Marson AG; Van Paesschen W; Kälviäinen R; Marovac J; Duncan B; Buyle S; Hallström Y; Hon P; Muscas GC; Newton M; Meencke HJ; Smith PE; Pohlmann-Eden B;
J Neurol Neurosurg Psychiatry; 2013 Oct; 84(10):1138-47. PubMed ID: 22933814
[TBL] [Abstract][Full Text] [Related]
14. Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study.
Nabors LB; Fink KL; Mikkelsen T; Grujicic D; Tarnawski R; Nam DH; Mazurkiewicz M; Salacz M; Ashby L; Zagonel V; Depenni R; Perry JR; Hicking C; Picard M; Hegi ME; Lhermitte B; Reardon DA
Neuro Oncol; 2015 May; 17(5):708-17. PubMed ID: 25762461
[TBL] [Abstract][Full Text] [Related]
15. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.
Gramatzki D; Kickingereder P; Hentschel B; Felsberg J; Herrlinger U; Schackert G; Tonn JC; Westphal M; Sabel M; Schlegel U; Wick W; Pietsch T; Reifenberger G; Loeffler M; Bendszus M; Weller M
Neurology; 2017 Apr; 88(15):1422-1430. PubMed ID: 28298550
[TBL] [Abstract][Full Text] [Related]
16. Revisiting Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients with Glioblastoma-Proteomic Alteration and Comparison Analysis with the Standard-of-Care Chemoirradiation.
Krauze AV; Zhao Y; Li MC; Shih J; Jiang W; Tasci E; Cooley Zgela T; Sproull M; Mackey M; Shankavaram U; Tofilon P; Camphausen K
Biomolecules; 2023 Oct; 13(10):. PubMed ID: 37892181
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of therapy-induced myelosuppression in newly diagnosed glioblastoma.
Le Rhun E; Oppong FB; Vanlancker M; Stupp R; Nabors B; Chinot O; Wick W; Preusser M; Gorlia T; Weller M
Neuro Oncol; 2022 Sep; 24(9):1533-1545. PubMed ID: 35312789
[TBL] [Abstract][Full Text] [Related]
18. Prognostic relevance of epilepsy at presentation in glioblastoma patients.
Berendsen S; Varkila M; Kroonen J; Seute T; Snijders TJ; Kauw F; Spliet WG; Willems M; Poulet C; Broekman ML; Bours V; Robe PA
Neuro Oncol; 2016 May; 18(5):700-6. PubMed ID: 26420896
[TBL] [Abstract][Full Text] [Related]
19. Effect of anti-epileptic drugs on the survival of patients with glioblastoma multiforme: A retrospective, single-center study.
Ryu JY; Min KL; Chang MJ
PLoS One; 2019; 14(12):e0225599. PubMed ID: 31790459
[TBL] [Abstract][Full Text] [Related]
20. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
Stupp R; Hegi ME; Neyns B; Goldbrunner R; Schlegel U; Clement PM; Grabenbauer GG; Ochsenbein AF; Simon M; Dietrich PY; Pietsch T; Hicking C; Tonn JC; Diserens AC; Pica A; Hermisson M; Krueger S; Picard M; Weller M
J Clin Oncol; 2010 Jun; 28(16):2712-8. PubMed ID: 20439646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
